1. Home
  2. ABSI
  3. Earnings

AI Earnings Predictions for Absci Corporation (ABSI)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-2.55%

$9.79

0% positive prob.

5-Day Prediction

-9.04%

$9.14

0% positive prob.

20-Day Prediction

-0.09%

$10.04

0% positive prob.

Price at prediction: $10.05 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -2.55% -9.04% -0.09% 100.0% Pending
Q2 2026 SELL -2.78% -9.29% +0.57% 100.0% Pending
Q1 2026 SELL -3.41% -9.88% -0.40% 100.0% -2.89%
Q3 2025 SELL -1.27% -10.13% -4.24% 100.0% -15.63%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 12, 2026 · 100% conf.

AI Prediction SELL

1D

-2.55%

$9.79

Act: -7.84%

5D

-9.04%

$9.14

20D

-0.09%

$10.04

Price: $10.05 Prob +5D: 0% AUC: 1.000
0001672688-26-000150

EX-99.1

2 exhibit991-2026q310xqpr.htm

EX-99.1

Document

Exhibit 99.1

Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results

ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month

Announced preliminary details for Phase 2 STORYLINE™ trial of ABS-201 for endometriosis

Appointed former Galderma executive Gerry Muhle as Chief Commercial Officer

VANCOUVER, Wash. and NEW YORK, November 12, 2026 – Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended September 30, 2026.

“As we approach our first look at proof-of-concept data for ABS-201 next month, followed by full data early next year, we are excited for the opportunity to potentially demonstrate our program's ability to stimulate hair regrowth in a convenient and durable way,” said Sean McClain, Founder and CEO. “As ABS-201 progresses through the clinic, we have begun building our commercial infrastructure to support this and potential future programs. In line with that strategy, we are thrilled to be welcoming Gerry Muhle to Absci as our Chief Commercial Officer, whose experience we believe will position ABS-201 and our expanding program pipeline for success.”

Recent Highlights

•Continuing to dose participants with pattern hair loss (PHL) in multiple ascending dose (MAD) portion of the HEADLINE trial. Absci anticipates reporting 13-week interim proof-of-concept data from this study in December 2026 and full 26-week proof-of-concept data in early 2027.

•Announced additional details for Absci's planned global, multi-center Phase 2 STORYLINE clinical trial evaluating ABS-201 for endometriosis. Absci anticipates initiation of this Phase 2 clinical trial in mid-2027.

•Appointed former Galderma executive Gerry Muhle as Chief Commercial Officer. Muhle brings over 25 years of experience across pharma, aesthetics, and consumer brands, and joins Absci as the company continues to build its commercial infrastructure to support its wholly-owned programs.

Prolactin (PRL) Program Portfolio

Exhibit 99.1

•ABS-201 for Pattern Hair Loss: ABS-201, currently undergoing Phase 1/2a studies, is being developed for pattern hair loss (PHL). Absci believes that ABS-201, if successfully developed and approved, could provide a significant new category of PHL treatment that offers the potential for durable hair growth with a convenient administration profile. In June, Absci announced positive interim Phase 1 data from the HEADLINE trial, demonstrating that the study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts. Additionally, the estimated half-life of at least 65 days supports the potential for ABS-201's targeted dosing interval of two or three injections over a six-month period. Absci anticipates reporting 13-week interim proof-of-concept data in December 2026 and full 26-week proof-of-concept data in early 2027.

•ABS-201 for Endometriosis: Endometriosis is a condition that impacts a large, underserved patient population with significant unmet medical need and poor standard of care. Endometriosis is prevalent in up to 10% of women worldwide, including an estimated 9 million women in the U.S., and there is currently no FDA-approved disease-modifying therapy. ABS-201 for endometriosis represents a novel non-sex steroid hormone mechanism, with potential to be disease-modifying, act on both pain and lesion growth, and offer an improved safety profile. With the safety, tolerability, and PK data being generated for ABS-201 in the company’s ongoing HEADLINE trial, Absci anticipates initiation of the Phase 2 STORYLINE trial for endometriosis in mid-2027. The planned Phase 2, double-blind, randomized, placebo-controlled trial would assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain as reported via patient-reported measures. For this trial, Absci anticipates recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance. Absci is designing STORYLINE as a dose-ranging trial, anticipating testing two or three dose levels that will be confirmed following review of HEADLINE data.

•ABS-202 for Undisclosed I&I Indication: ABS-202 is an anti-PRLR antibody in preclinical development for an undisclosed I&I indication.

Other Internal Pipeline Programs and Partnerships

Absci continues to advance its ongoing drug creation partnered programs, as well as partnering discussions for other internal programs at various stages of preclinical and clinical development.

Recent Publications, Pres

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 11, 2026 · 100% conf.

AI Prediction SELL

1D

-2.78%

$9.15

Act: +0.96%

5D

-9.29%

$8.54

20D

+0.57%

$9.46

Price: $9.41 Prob +5D: 0% AUC: 1.000
0001672688-26-000134

EX-99.1

2 exhibit991-2026q210xqpr.htm

EX-99.1

Document

Exhibit 99.1

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201

Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company

Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028

VANCOUVER, Wash. and NEW YORK, August 11, 2026 – Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026.

“The positive Phase 1 interim data from our HEADLINE trial, combined with our strengthened balance sheet and advancing platform, position us well for what comes next,” said Sean McClain, Founder and CEO. “We are fast approaching defining moments for Absci, with interim proof-of-concept data for pattern hair loss later this year and our full 26-week readout in early 2027. These results have the potential to demonstrate ABS-201's regenerative mechanism and change the treatment paradigm for the millions of people living with pattern hair loss. And this is just the beginning for our prolactin receptor franchise within our overall proprietary pipeline, with endometriosis expansion ahead.”

Recent Highlights

•Reported positive interim Phase 1 data from Absci's first-in-human trial of ABS-201 (anti-PRLR antibody). Blinded, aggregate interim data suggest study drug was well tolerated and exhibited a favorable safety and tolerability profile. Based on available interim pharmacokinetic (PK) data across all four single ascending dose (SAD) cohorts, half-life for ABS-201 is estimated to be at least 65 days. These results support the potential for dosing two or three times over a six month period, pending confirmation through continued follow-up across all cohorts.

•Completed $100 million underwritten offering, including a $40 million strategic equity investment from Eli Lilly & Company, and participation from leading financial institutions including Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and a large investment management firm.

Exhibit 99.1

•Continuing to dose participants with pattern hair loss (PHL) in multiple ascending dose (MAD) portion of the HEADLINE trial. Absci anticipates reporting interim proof-of-concept data from this study in the second half of 2026 and full proof-of-concept data in early 2027.

Prolactin (PRL) Program Portfolio

•ABS-201 for Pattern Hair Loss: ABS-201, currently undergoing Phase 1/2a studies, is being developed for pattern hair loss (PHL). Absci believes that ABS-201, if successfully developed and approved, could provide a significant new category of PHL treatment that offers the potential for durable hair growth with a convenient administration profile. In June, Absci announced positive interim Phase 1 data from the HEADLINE trial, demonstrating that the study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts. Additionally, the estimated half-life of at least 65 days supports the potential for ABS-201's targeted dosing interval of two or three injections over a six-month period. Absci anticipates reporting interim proof-of-concept data in the second half of 2026 and full proof-of-concept data in early 2027.

•ABS-201 for Endometriosis: Endometriosis is a condition that impacts a large, underserved patient population with significant unmet medical need and poor standard of care. Endometriosis is prevalent in up to 10% of women worldwide, including an estimated 9 million women in the U.S., and there is currently no FDA-approved disease-modifying therapy. ABS-201 for endometriosis represents a novel non-sex steroid hormone mechanism, with potential to be disease-modifying, act on both pain and lesion growth, and offer an improved safety profile. With the safety, tolerability, and PK data generated in the ongoing HEADLINE trial, Absci anticipates initiation of a Phase 2 clinical trial for endometriosis in the fourth quarter of 2026, with potential proof-of-concept data in the second half of 2027.

•ABS-202 for Undisclosed I&I Indication: ABS-202 is an anti-PRLR antibody in preclinical development for an undisclosed I&I indication.

Other Internal Pipeline Programs and Partnerships

Absci continues to advance its ongoing drug creation partnered programs, as well as partnering discussions for other internal programs at various stages of preclinical and clinical development.

Absci’s new partnership with Eli Lilly is tailored around the clinical development strategy for ABS-201, and does not confer any program rights to Eli Lilly. As part of Eli Lilly’s $40 million strategic investment in Absci, a representative from Eli Lilly has joined Absci’s Endometriosis Advisory Board.

R

2026
Q1

Q1 2026 Earnings

8-K SELL

May 7, 2026 · 100% conf.

AI Prediction SELL

1D

-3.41%

$5.51

Act: +4.12%

5D

-9.88%

$5.14

Act: -2.89%

20D

-0.40%

$5.68

Act: +11.31%

Price: $5.71 Prob +5D: 0% AUC: 1.000
0001672688-26-000086

EX-99.1

2 exhibit991-2026q110xqpr.htm

EX-99.1

Document

Exhibit 99.1

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data

Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval

Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial

Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline

VANCOUVER, Wash. and NEW YORK, May 7, 2026 – Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended March 31, 2026.

“2026 is going to be a data-rich year for Absci with multiple readouts ahead,” said Sean McClain, Founder and CEO. “ABS-201, our AI-designed long-acting antibody against the prolactin receptor, has the potential to be the first new mechanism of action in androgenetic alopecia in nearly three decades, with a targeted dosing interval of just a few times a year. ABS-202, announced today, extends our prolactin work into a third therapeutic area. We're combining Origin with the prolactin biology we've built to go after a target that has been overlooked.”

Recent Highlights

•Successfully dosed all four planned healthy volunteer single ascending dose (SAD) cohorts of ongoing Phase 1/2a HEADLINE trial. To date, ABS-201 continues to be well tolerated, with favorable emerging safety data. Additionally, preliminary PK modeling from the company's ongoing clinical trial supports ABS-201's targeted dosing interval of two or three injections over a six-month period. Absci has also initiated dosing of the first multiple ascending dose (MAD) cohort of AGA participants. Absci anticipates reporting preliminary safety, tolerability, and PK data in the second quarter of 2026.

•Expanded internal program pipeline with addition of ABS-202, a second novel anti-PRLR antibody currently in preclinical development for an undisclosed indication in inflammation and immunology (I&I).

Exhibit 99.1

•Launched endometriosis clinical advisory board for ABS-201 program, consisting of endometriosis and clinical development experts with backgrounds from renowned institutions including the Yale University School of Medicine, Duke University School of Medicine, UCSF, and the Mayo Clinic.

Prolactin (PRL) Program Portfolio

Absci is leveraging its leadership in prolactin biology to expand its pipeline of programs centered on prolactin and the prolactin receptor (PRLR). This growing portfolio currently includes:

•ABS-201 for Androgenetic Alopecia: ABS-201, currently undergoing Phase 1/2a studies, is being developed for androgenetic alopecia (AGA), commonly known as male and female pattern hair loss. Absci believes that ABS-201, if successfully developed and approved, could provide a significant new category of AGA treatment that offers potentially durable hair growth with a convenient administration profile. Today, Absci announced that it has successfully dosed all four planned healthy volunteer single ascending dose (SAD) cohorts of the ongoing Phase 1/2a HEADLINE trial. To date, ABS-201 continues to be well tolerated, with favorable emerging safety data. Additionally, preliminary PK modeling from the company's ongoing clinical trial supports ABS-201's targeted dosing interval of two or three injections over a six-month period. Absci has also initiated dosing of the first multiple ascending dose (MAD) cohort of AGA participants. Absci anticipates reporting preliminary safety, tolerability, and PK data in the second quarter of 2026, with interim proof-of-concept data in the second half of 2026 and full proof-of-concept data in early 2027.

•ABS-201 for Endometriosis: Endometriosis is a condition that impacts a large, underserved patient population with significant unmet medical need and poor standard of care. Endometriosis is prevalent in up to 10% of women worldwide, including an estimated 9 million women in the U.S., and there is currently no FDA-approved disease-modifying therapy. ABS-201 for endometriosis represents a novel non-sex steroid hormone mechanism, with potential to be disease-modifying, act on both pain and lesion growth, and offer an improved safety profile. Absci anticipates initiation of a Phase 2 clinical trial for endometriosis in the fourth quarter of 2026, with potential proof-of-concept data in the second half of 2027.

•ABS-202 for Undisclosed I&I Indication: Today, Absci announced the addition of ABS-202 to its portfolio of internal pipeline programs. ABS-202 is an anti-PRLR antibody in preclinical development for an undisclosed I&I indication.

Exhibit 99.1

Other Internal Pipeline and Partnered Programs

Absci continues to advance partnering discussions for other in

About Absci Corporation (ABSI) Earnings

This page provides Absci Corporation (ABSI) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ABSI's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: